Literature DB >> 24012616

The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.

Sha Sha Zeng1, Taro Yamashita2, Mitsumasa Kondo1, Kouki Nio1, Takehiro Hayashi1, Yasumasa Hara1, Yoshimoto Nomura1, Mariko Yoshida1, Tomoyuki Hayashi1, Naoki Oishi1, Hiroko Ikeda3, Masao Honda1, Shuichi Kaneko1.   

Abstract

BACKGROUND & AIMS: Recent evidence suggests that hepatocellular carcinoma can be classified into certain molecular subtypes with distinct prognoses based on the stem/maturational status of the tumor. We investigated the transcription program deregulated in hepatocellular carcinomas with stem cell features.
METHODS: Gene and protein expression profiles were obtained from 238 (analyzed by microarray), 144 (analyzed by immunohistochemistry), and 61 (analyzed by qRT-PCR) hepatocellular carcinoma cases. Activation/suppression of an identified transcription factor was used to evaluate its role in cell lines. The relationship of the transcription factor and prognosis was statistically examined.
RESULTS: The transcription factor SALL4, known to regulate stemness in embryonic and hematopoietic stem cells, was found to be activated in a hepatocellular carcinoma subtype with stem cell features. SALL4-positive hepatocellular carcinoma patients were associated with high values of serum alpha fetoprotein, high frequency of hepatitis B virus infection, and poor prognosis after surgery compared with SALL4-negative patients. Activation of SALL4 enhanced spheroid formation and invasion capacities, key characteristics of cancer stem cells, and up-regulated the hepatic stem cell markers KRT19, EPCAM, and CD44 in cell lines. Knockdown of SALL4 resulted in the down-regulation of these stem cell markers, together with attenuation of the invasion capacity. The SALL4 expression status was associated with histone deacetylase activity in cell lines, and the histone deacetylase inhibitor successfully suppressed proliferation of SALL4-positive hepatocellular carcinoma cells.
CONCLUSIONS: SALL4 is a valuable biomarker and therapeutic target for the diagnosis and treatment of hepatocellular carcinoma with stem cell features.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFP; CSC; Cancer stem cell; Chemosensitivity; EpCAM; Gene expression profile; HCC; HDAC; Hepatocellular carcinoma; HpSC-HCC; MH-HCC; NuRD; SAHA; SALL4; SBHA; Sal-like 4 (Drosophila); alpha fetoprotein; cancer stem cell; epithelial cell adhesion molecule; hepatic stem cell-like HCC; hepatocellular carcinoma; histone deacetylase; mature hepatocyte-like HCC; nucleosome remodeling and deacetylase; qRT-PCR; quantitative reverse transcription-polymerase chain reaction; suberic bis-hydroxamic acid; suberoylanilide hydroxamic acid

Mesh:

Substances:

Year:  2013        PMID: 24012616     DOI: 10.1016/j.jhep.2013.08.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  57 in total

Review 1.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

2.  Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.

Authors:  Lei Zhang; Yong Yan; Ying Jiang; Jun Qian; Lei Jiang; Guohan Hu; Yicheng Lu; Chun Luo
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

Review 3.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

4.  Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.

Authors:  Li Liu; Liang Liu; Lai-Han Leung; Austin J Cooney; Changyi Chen; Todd K Rosengart; Yupo Ma; Jianchang Yang
Journal:  J Biol Chem       Date:  2015-03-03       Impact factor: 5.157

5.  Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.

Authors:  Bee Hui Liu; Chacko Jobichen; C S Brian Chia; Tim Hon Man Chan; Jing Ping Tang; Theodora X Y Chung; Jia Li; Anders Poulsen; Alvin W Hung; Xiaoying Koh-Stenta; Yaw Sing Tan; Chandra S Verma; Hong Kee Tan; Chan-Shuo Wu; Feng Li; Jeffrey Hill; Joma Joy; Henry Yang; Li Chai; J Sivaraman; Daniel G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-05       Impact factor: 11.205

6.  Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.

Authors:  Rajagopal N Aravalli; Neil C Talbot; Clifford J Steer
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

Review 7.  Functional and clinical significance of SALL4 in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik
Journal:  Tumour Biol       Date:  2016-07-21

8.  Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.

Authors:  Fei Yin; Xin Han; Shu-Kun Yao; Xiao-Ling Wang; Hui-Chai Yang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 9.  Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells.

Authors:  Taro Yamashita; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2014-03-20       Impact factor: 7.527

10.  Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Muhammad Usman Akbar; Lu Zhang; Yang An; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.